Skip to main content

Drug Interactions between Jakafi and ritlecitinib

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

ruxolitinib ritlecitinib

Applies to: Jakafi (ruxolitinib) and ritlecitinib

GENERALLY AVOID: Coadministration of ritlecitinib with other immunosuppressive agents may potentiate the risk of infections as well as malignancies, including non-melanoma skin cancer (NMSC). Serious infections have been reported in patients who have received ritlecitinib. The most common serious infections reported with ritlecitinib included appendicitis, pneumonia, COVID-19, and sepsis. Herpes virus reactivation (e.g., herpes zoster) was also reported during clinical studies with ritlecitinib, as well as malignancies including NMSC.

MANAGEMENT: The safety and efficacy of ritlecitinib in combination with immunosuppressive agents has not been evaluated. Some authorities recommend that the concomitant use of ritlecitinib with other Janus Kinus (JAK) inhibitors, biologic immunomodulators, cyclosporine, or other potent immunosuppressants should be avoided (US). Patients receiving ritlecitinib should be closely monitored for the development of signs and symptoms of infection during and after treatment, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy. If a serious infection develops, ritlecitinib therapy should be interrupted until the infection is controlled.

References

  1. (2023) "Product Information. Litfulo (ritlecitinib)." Pfizer U.S. Pharmaceuticals Group

Switch to consumer interaction data

Drug and food interactions

Moderate

ruxolitinib food

Applies to: Jakafi (ruxolitinib)

GENERALLY AVOID: Grapefruit juice may increase the plasma concentrations of ruxolitinib. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.

MANAGEMENT: Patients treated with ruxolitinib should avoid consumption of grapefruit, grapefruit juice, and any supplement containing grapefruit extract. Ruxolitinib may be administered with or without food.

References

  1. (2011) "Product Information. Jakafi (ruxolitinib)." Incyte Corporation

Switch to consumer interaction data

Therapeutic duplication warnings

Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.

Duplication

Multikinase inhibitors

Therapeutic duplication

The recommended maximum number of medicines in the 'multikinase inhibitors' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'multikinase inhibitors' category:

  • Jakafi (ruxolitinib)
  • ritlecitinib

Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer